TY - JOUR
T1 - Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation
AU - The IeDEA, COHERE, PHACS and IMPAACT 219C Collaborations Writing Group
AU - Panayidou, Klea
AU - Davies, Mary Ann
AU - Anderegg, Nanina
AU - Egger, Matthias
AU - Fatti, Geoffrey
AU - Vinikoor, Michael
AU - Sawry, Shobna
AU - Ehmer, Jochen
AU - Eley, Brian
AU - Phiri, Sam
AU - Technau, Karl G.Ü.Nter
AU - Chimbetete, Cleophas
AU - Rabie, Helena
AU - Boulle, Andrew
AU - Tanser, Frank
AU - Wood, Robin
AU - Wools-Kaloustian, Kara
AU - Vreeman, Rachel
AU - Oyaro, Patrick
AU - Ayaya, Samuel
AU - Nakigozi, Gertrude
AU - Musick, Beverley
AU - Yiannoutsos, Constantin
AU - Amorissani-Folquet, Madeleine
AU - Takassi, Elom
AU - Sylla, Mariam
AU - Renner, Lorna
AU - Malateste, Karen
AU - Desmonde, Sophie
AU - Leroy, Valériane
AU - Kurniati, N.
AU - Hansudewechakul, Rawiwan
AU - Nguyen, Lam Van
AU - Ly, Penh Sun
AU - Truong, Khanh Huu
AU - Kariminia, Azar
AU - Sohn, Annette H.
AU - Edmonds, Andrew
AU - Yumo, Habakkuk Azinyui
AU - Dusingize, Jean Claude
AU - Yotebieng, Marcel
AU - Judd, Ali
AU - Rojo, Pablo
AU - Smit, Colette
AU - Grabar, Sophie
AU - Warszwarski, Josiane
AU - Chene, Genevieve
AU - Wati, D. K.
AU - Kurniati, N.
AU - Muktiarti, D.
N1 - Publisher Copyright:
© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease. Methods: We included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines. Results: We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions in 2006 (low-, lower middle- and upper middle-income countries) and 2010 (all countries). Conclusions: By 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced disease. However, considerable global inequity remains, in 2013, >40% of children in low- and middle-income countries started cART with severe immunodeficiency compared to <20% in high-income countries.
AB - Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease. Methods: We included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines. Results: We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions in 2006 (low-, lower middle- and upper middle-income countries) and 2010 (all countries). Conclusions: By 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced disease. However, considerable global inequity remains, in 2013, >40% of children in low- and middle-income countries started cART with severe immunodeficiency compared to <20% in high-income countries.
KW - advanced HIV disease
KW - antiretroviral therapy
KW - Asia
KW - Caribbean
KW - CD4 cell count
KW - Central and South America
KW - Europe
KW - North America
KW - sub-Saharan Africa
KW - WHO guidelines
UR - http://www.scopus.com/inward/record.url?scp=85057606927&partnerID=8YFLogxK
U2 - 10.1002/jia2.25200
DO - 10.1002/jia2.25200
M3 - Article
C2 - 30614622
AN - SCOPUS:85057606927
SN - 1758-2652
VL - 21
JO - Journal of the International AIDS Society
JF - Journal of the International AIDS Society
IS - 11
M1 - e25200
ER -